Which gene is most strongly correlated with both axial spondyloarthritis and uveitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HLA-B27 is the Gene Most Strongly Correlated with Both Axial Spondyloarthritis and Uveitis

HLA-B27 is definitively the gene with the strongest correlation to both axial spondyloarthritis (axSpA) and acute anterior uveitis (AAU), representing the dominant shared genetic risk factor between these two conditions. 1

Strength of HLA-B27 Association

In Axial Spondyloarthritis

  • HLA-B27 is positive in 74% to 89% of patients with axSpA, demonstrating an exceptionally strong association 1
  • Among HLA-B27-positive first-degree relatives, approximately 25% developed axSpA over 35 years of follow-up, compared to only 3% of HLA-B27-negative relatives 1
  • The association is so robust that HLA-B27 positivity increases the likelihood of peripheral spondyloarthritis and is a key diagnostic consideration 1

In Uveitis

  • Acute anterior uveitis occurred significantly more frequently in first-degree relatives who later developed axSpA (odds ratio 4.7; 95% CI 2.2-10.5), with HLA-B27 being the underlying genetic link 1
  • HLA-B27-associated AAU shares the same genetic architecture as axSpA, with HLA-B27 showing association P<10^-300 in comparative studies 2
  • Uveitis serves as a potential predictor of axSpA development, mediated through the shared HLA-B27 genetic pathway 1

Additional Genetic Factors (Secondary to HLA-B27)

While HLA-B27 dominates, other genes show associations but with substantially weaker effects:

ERAP1

  • Shows association with both conditions, but this association is restricted to HLA-B27-positive disease 2, 3
  • Demonstrates differential impact on AAU risk compared to AS alone, suggesting gene-environment interaction with HLA-B27 2

HLA-A*02:01

  • Shows secondary association with AAU (P=6×10^-8), but far weaker than HLA-B27 2

Other MHC Region Genes

  • PSORS1C3 (P=4.7×10^-5) and TAP2 (P=1.1×10^-5) show secondary independent associations within the major histocompatibility complex 2

Clinical Implications

Diagnostic Considerations

  • Spondyloarthritis should not be ruled out based solely on negative HLA-B27 testing, as the disease can occur in HLA-B27-negative individuals, though less commonly 1
  • HLA-B27 positivity combined with clinical features (inflammatory back pain, uveitis, family history) substantially increases diagnostic probability 1

Prognostic Reassurance

  • HLA-B27 carriage alone does not adversely impact survival in individuals without axSpA, including no increased cardiovascular mortality 1
  • No significant mortality differences exist between HLA-B27-positive and HLA-B27-negative patients within either radiographic or non-radiographic axSpA groups 1

Mechanistic Understanding

The pathogenic mechanism involves:

  • Expanded CD8+ T cell subsets bearing unique T cell receptor motifs (TRAV21/TRBV9) in HLA-B27-positive patients with axSpA or AAU 4
  • These T cells can bind both self-derived and bacterial peptides, supporting the "arthritogenic peptide" hypothesis 4
  • Evidence suggests early antigen exposure and differentiation of pathogenic CD8+ T cells may occur in enteric organs, with mucosal signatures found in ocular and synovial T cells 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.